Cero Therapeutics Regains Compliance with Nasdaq Bid Price Requirement, Avoids Delisting

Reuters
07/08
Cero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Regains Compliance with Nasdaq Bid Price Requirement, Avoids Delisting

Cero Therapeutics Holdings Inc. recently faced a potential delisting from The Nasdaq Capital Market due to its common stock trading below the minimum required bid price of $1.00 per share for a 30-day period ending on June 9, 2025. However, after appealing the delisting decision, the company successfully regained compliance with Nasdaq's listing requirements by July 7, 2025. As a result, the planned delisting hearing was canceled, and Cero Therapeutics' stock will continue to be listed and traded on the Nasdaq Capital Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-061911), on July 08, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10